Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
about
Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infectionsRAGE: a new frontier in chronic airways diseaseEffect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPARγDeletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPARγTreating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infectionVascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ω-HydroxylasesThe PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.Differential expression of vitamin E and selenium-responsive genes by disease severity in chronic obstructive pulmonary diseaseThe peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy.Resolvins: natural agonists for resolution of pulmonary inflammation.Chronic exposure to perfluorinated compounds: Impact on airway hyperresponsiveness and inflammationRole of prostacyclin in pulmonary hypertension.Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice.Circulating MicroRNAs: Association with Lung Function in Asthma.PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases.PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy.Vascular endothelial overexpression of human CYP2J2 (Tie2-CYP2J2 Tr) modulates cardiac oxylipin profiles and enhances coronary reactive hyperemia in mice.A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferationExpression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue.Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammationChronic obstructive pulmonary disease and lung cancer: new molecular insights.Emerging drugs for chronic obstructive pulmonary disease.PPARγ inhibits airway epithelial cell inflammatory response through a MUC1-dependent mechanismInvolvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo.PPAR-γ promotes type 2 immune responses in allergy and nematode infection.15-Deoxy-Delta-12,14-Prostaglandin J2 Inhibits Lung Inflammation and Remodeling in Distinct Murine Models of Asthma.Mediators and receptors in the resolution of inflammation: drug targeting opportunities.Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-gamma agonists in bronchial epithelial cells.Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-γ ligands in a cyclooxygenase-2-dependent manner.Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A2A receptor and plasma oxylipins.In vivo imaging reveals selective PPAR activity in the skin of peroxisome proliferator-activated receptor responsive element-luciferase reporter mice.Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation.Peroxisome proliferator-activated receptor-γ in induced sputum is correlated with MMP-9/TIMP-1 imbalance and formation of emphysema in COPD patients.Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway.Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats.PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.
P2860
Q26825122-04E250EE-1095-41AA-8B39-479D503156EDQ27025295-7EC70256-B67D-43ED-8DEA-CFE1B525CDE9Q28388202-D8EE3CE6-EE99-4CA5-9294-FAA0F0A092D3Q28396011-DF8AB08E-1F09-40B3-94A7-5D2AFCE0F026Q28748904-67E79AFD-3B85-49EB-99A5-E83884364F01Q29248910-CEDE656B-B8FB-4CCB-A384-6C427C62C075Q33538017-E9D24E12-61C4-4C1D-8CB5-09ECDEABCAC4Q33766550-49BB8916-89BE-4A04-A1E3-A4E8F3C4D662Q33806178-40618428-3EE1-47EB-A054-F391835A4DDFQ34448487-AEB7B7FD-D4F7-4468-A9A8-4594DD7B8419Q34519367-B6B9E5A2-B7F9-4738-9824-1881563E39BBQ35165100-E0F8216F-6F92-4167-8EC2-8D0C59492CBCQ35397274-AFE49FD1-1755-4D66-BBB8-93C034FB51E6Q36065044-CA8798A0-B3F7-40B8-AAFE-11692FFD837AQ36065220-94E5F763-60CB-4996-8A36-4A5655F8C3B2Q36200396-386C3594-E372-4E93-B107-649A2A72C405Q36318247-E4D73B47-007D-46E2-B6EB-2BA9CB6AB1D3Q36324984-08290B3E-3362-44D6-BFB3-468283E15444Q36443665-561FC862-2DF2-405D-8302-846E28083CB2Q36603243-C9DD98F5-A5BD-4A56-9DEB-984249D38250Q36809430-AB756FAE-3853-49A3-8F0F-A1D267811757Q37120799-EA16EA70-58CB-4842-971A-8605B34E294EQ37856648-1180641B-5718-4081-AFDE-08E3274221D9Q37984088-D9A7568A-4A53-4957-BD45-2892E4682E2FQ39407900-296683D6-3CFE-417A-830F-4784BDEE463AQ39750509-A244DDE1-AD2C-42C3-BF72-81C9C33B813CQ40103728-3B8845CB-4210-4ED9-8F51-7306172F1FCCQ40996271-29E5B43E-CE32-4D3C-8A89-82D80FA9E100Q42681904-6BDF7AC4-B002-4AAC-936C-2A8F4FE7A30AQ42708599-EBB037C3-D6AF-48A9-89E6-1DC37EAA8A62Q42784201-F31C4FA6-104B-44C8-AE8D-99A80EDC24CFQ45067047-DCFBB1A2-FD66-43A8-B9D9-09E07970F005Q46162360-CAD7AB40-AFB1-4B63-8FEF-C6A8FDC2D671Q46256338-98DF4B76-453A-4412-9CEE-7522622D53A4Q47101352-F0701269-120D-49CD-90D5-ED8D977094A8Q47218030-6D3001D8-D4C7-4BAC-94A5-0FC89807A3A1Q49484413-D9245E9E-CCEA-45ED-B245-68B9DC60B272Q49953684-4CA15D19-5C8A-4420-8745-6ABD14C47D6D
P2860
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@en
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@nl
type
label
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@en
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@nl
prefLabel
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@en
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@nl
P2860
P921
P1476
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
@en
P2093
Jane A Mitchell
Maria G Belvisi
P2860
P304
P356
10.1111/J.1476-5381.2009.00373.X
P407
P577
2009-08-24T00:00:00Z
2009-10-01T00:00:00Z